| ［1］ |
滕熠, 张晓丹, 夏昌发, 等. 中国与全球癌症发病、死亡和患病对比及其预测分析: GLOBOCAN 2022数据解读[J]. 中华肿瘤防治杂志, 2024, 31(23): 1413–1420.
|
| ［2］ |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229–263.
|
| ［3］ |
Ilic M, Ilic I. Epidemiology of stomach cancer[J]. World J Gastroenterol, 2022, 28(12): 1187–1203.
|
| ［4］ |
Ajani JA, D’amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2. 2022, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2022, 20(2): 167–192.
|
| ［5］ |
Bartley AN, Washington MK, Colasacco C, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology[J]. J Clin Oncol, 2017, 35(4): 446–464.
|
| ［6］ |
Moelans CB, Milne AN, Morsink FH, et al. Low frequency of HER2 amplification and overexpression in early onset gastric cancer[J]. Cell Oncol (Dordr), 2011, 34(2): 89–95.
|
| ［7］ |
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687–697.
|
| ［8］ |
Uzunparmak B, Haymaker C, Raso G, et al. HER2-low expression in patients with advanced or metastatic solid tumors[J]. Ann Oncol, 2023, 34(11): 1035–1046.
|
| ［9］ |
Yu M, Liang Y, Li L, et al. Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer[J]. Transl Oncol, 2023, 29: 101624.
|
| ［10］ |
Peng Z, Liu T, Wei J, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: A single-arm phase Ⅱ study[J]. Cancer Commun (Lond), 2021, 41(11): 1173–1182.
|
| ［11］ |
Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: A dose-expansion, phase 1 study[J]. Lancet Oncol, 2019, 20(6): 827–836.
|
| ［12］ |
Xu Y, Wang Y, Gong J, et al. Phase Ⅰ study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors[J]. Gastric Cancer, 2021, 24(4): 913–925.
|
| ［13］ |
Yamaguchi K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase Ⅱ trial[J]. J Clin Oncol, 2023, 41(4): 816–825.
|
| ［14］ |
Bai X, Sun P, Wang X, et al. Structure and dynamics of the EGFR/HER2 heterodimer[J]. Cell Discov, 2023, 9(1): 18.
|
| ［15］ |
Trenker R, Diwanji D, Bingham T, et al. Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation[J]. eLife, 2024, 12(12): RP92873.
|
| ［16］ |
Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation[J]. Trends Biochem Sci, 2011, 36(6): 320–328.
|
| ［17］ |
Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition[J]. Nat Rev Mol Cell Biol, 2014, 15(3): 178–196.
|
| ［18］ |
Giugliano F, Curigliano G, Tarantino P. HER2-low expression in breast oncology: treatment implications in the smart chemotherapy era[J]. Eur J Cancer Prev, 2023, 32(2): 149–154.
|
| ［19］ |
Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with her2-low-expressing advanced breast cancer: results from a phase Ⅰb study[J]. J Clin Oncol, 2020, 38(17): 1887–1896.
|
| ［20］ |
Sasso J M, Tenchov R, Bird R, et al. The evolving landscape of antibody-drug conjugates: in depth analysis of recent research progress[J]. Bioconjug Chem, 2023, 34(11): 1951–2000.
|
| ［21］ |
Petricevic B, Laengle J, Singer J, et al. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients[J]. J Transl Med, 2013, 11: 307.
|
| ［22］ |
Shimozaki K, Fukuoka S, Ooki A, et al. HER2-low gastric cancer: is the subgroup targetable?[J]. ESMO Open, 2024, 9(9): 103679.
|
| ［23］ |
Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?[J]. Br J Cancer, 2017, 117(12): 1736–1742.
|
| ［24］ |
牟依琳, 林东亮, 赵树超, 等. HER2低表达胃腺癌临床病理特征[J]. 临床与实验病理学杂志, 2025, 41(3): 334–339.
|
| ［25］ |
Narita Y, Mizuno T, Ishizuka Y, et al. Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: A retrospective observational study[J]. Oncologist, 2024: oyae328.
|
| ［26］ |
Nakayama I, Takahari D, Chin K, et al. Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma[J]. ESMO Open, 2023, 8(4): 101582.
|
| ［27］ |
Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study[J]. Lancet Oncol, 2018, 19(10): 1372–1384.
|
| ［28］ |
Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An international randomised, open-label, adaptive, phase 2/3 study[J]. Lancet Oncol, 2017, 18(5): 640–653.
|
| ［29］ |
Jin Y, Edalatian Zakeri S, Bahal R, et al. New technologies bloom together for bettering cancer drug conjugates[J]. Pharmacol Rev, 2022, 74(3): 680–711.
|
| ［30］ |
Barok M, Le Joncour V, Martins A, et al. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer[J]. Cancer Lett, 2020, 473: 156–163.
|
| ［31］ |
Zhang T, You L, Xu J, et al. Abstract LB031: SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles[J]. Cancer Res, 2023, 83(8): LB031.
|
| ［32］ |
Li J, Luo S, Liu T, et al. 684P phase Ⅰ trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)[J]. Ann Oncol, 2023, 34: S478.
|
| ［33］ |
Skidmore L, Sakamuri S, Knudsen NA, et al. ARX788, a site-specific anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers[J]. Mol Cancer Ther, 2020, 19(9): 1833–1843.
|
| ［34］ |
Zhang Y, Qiu MZ, Wang JF, et al. Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma[J]. Cell Rep Med, 2022, 3(11): 100814.
|
| ［35］ |
Shin SH, Park YH, Park SS, et al. An elaborate new linker system significantly enhances the efficacy of an HER2-antibody-drug conjugate against refractory HER2-positive cancers[J]. Adv Sci (Weinh), 2021, 8(23): e2102414.
|
| ［36］ |
Yu J, Fang T, Yun C, et al. Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers[J]. Front Mol Biosci, 2022, 9: 847835.
|
| ［37］ |
Xu J, Ying J, Liu R, et al. KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer[J]. Eur J Cancer, 2023, 178: 1–12.
|
| ［38］ |
Nie C, Xu W, Guo Y, et al. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: A multicenter real-world study[J]. BMC Cancer, 2023, 23(1): 1239.
|
| ［39］ |
Wang Y, Gong J, Wang A, et al. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: A multicentre, open label, dose escalation and expansion phase 1 trial[J]. EClinicalMedicine, 2024, 68: 102415.
|
| ［40］ |
Janjigian YY, Raoufmoghaddam S, Sztachelska M, et al. Phase 1b/2, open-label dose-escalation and-expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03)[J]. J Clin Oncol, 2024, 42(3_suppl): TPS424-TPS.
|
| ［41］ |
Makiyama A, Sukawa Y, Kashiwada T, et al. Randomized, phase Ⅱ study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study)[J]. J Clin Oncol, 2020, 38(17): 1919–1927.
|
| ［42］ |
Kim CG, Jung M, Kim HS, et al. Trastuzumab combined with ramucirumab and paclitaxel in patients with previously treated human epidermal growth factor receptor 2-positive advanced gastric or gastroesophageal junction cancer[J]. J Clin Oncol, 2023, 41(27): 4394–4405.
|